At IFM Therapeutics, we work to improve the lives of patients with inflammatory disorders and cancer by developing transformative medicines that precisely target the innate immune system, the body’s first line of immunological response and an essential component of immune function.
Location: United States, Massachusetts, Boston
Employees: 11-50
Total raised: $82.5M
Founded date: 2017
Investors 3
Funding Rounds 2
| Date | Series | Amount | Investors |
| 02.12.2019 | - | $55.5M | - |
| 22.06.2016 | Series A | $27M | - |
Mentions in press and media 13
| Date | Title | Description |
| 26.10.2020 | Former CEO of IFM Therapeutics launches new precision medicine startup with $108M | Gary Glick hasn’t stayed in one scientific venture for long. As a chemistry professor at the University of Michigan, he would change directions every three or four years. As chief executive of IFM Therapeutics until late last year, he's spu... |
| 11.12.2019 | Venture capital firm Omega Funds closes $438M Fund VI | “We believe this is the most exciting time to be investing in life sciences in a generation, but it requires diverse skills to capture the opportunity set,” Omega Managing Director Otello Stampacchia said in a statement. “At Omega, we have ... |
| 02.12.2019 | IFM Therapeutics Announces $55.5M Financing | BOSTON, MA, Privately-held biopharmaceutical company announced the closing of a $55.5 million financing. >> Click here for more funding data on IFM Therapeutics >> To export IFM Therapeutics funding data to PDF and Excel, cl... |
| 02.12.2019 | IFM Therapeutics Raises $55.5M; Appoints Dr. H. Martin Seidel as CEO | IFM Therapeutics (IFM), a privately-held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, today announced the closing of a $55.5 million financing and the launch of its third... |
| 02.12.2019 | IFM Therapeutics Raises $55.5M in Financing | IFM Therapeutics (IFM), a Boston, MA-based biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, closed a $55.5m financing. The round was led by new investor Omega Funds, with par... |
| 01.04.2019 | Novartis in nearly $1.6B deal to buy NASH-focused subsidiary of IFM Therapeutics | IFM, which focuses on developing therapies that modulate novel targets in the innate immune system, launched IFM Tre in July 2018, for the purpose of developing drugs in a class known as NLRP3 antagonists. The lead program in IFM Tre’s port... |
| 04.08.2017 | Term Sheet — Friday, Aug. 4 | MUPPETS GONE WILD Hello, it’s Jeff John Roberts, filling in while Erin is working on some longer-term projects. You can send your feedback here and follow me on Twitter here. Paid Content How can you protect what you can't see? From ExtraHo... |
| 22.06.2016 | Biopharmaceutical Company IFM Therapeutics Closes $27M Series A Financing | IFM Therapeutics, a Cambridge, Massachusetts-based biopharmaceutical company developing a portfolio of small molecules targeting the innate immune system, closed a $27m Series A financing. The round was led by Atlas Venture and Abingworth, ... |
| 22.06.2016 | IFM Therapeutics Raises $27M Series A | CAMBRIDGE, MA, Biopharmaceutical company developing a portfolio of first-in-class small molecules targeting the innate immune system, has closed a $27 million Series A financing. >> Click here for more funding data on IFM Therapeut... |
| 22.06.2016 | IFM Therapeutics Raises $27 Million Series A | CAMBRIDGE, Mass.--(BUSINESS WIRE)--IFM Therapeutics, a biopharmaceutical company developing a portfolio of first-in-class small molecules targeting the innate immune system, today announced the closing of a $27 million Series A financing le... |
Show more